Dangerous Drug: glyBURIDE(glye’ byoor ide)
Apo-Glyburide (CAN), DiaBeta, Gen-Glybe (CAN), Glibenclamide (CAN), Glynase PresTab, Novo-Glyburide (CAN), PMS-Glyburide (CAN), ratio-Glyburide (CAN)
PREGNANCY CATEGORY B
(GLYNASE)
PREGNANCY CATEGORY C
(DIABETA)
Drug Classes
Antidiabetic
Sulfonylurea
Therapeutic Actions
Stimulates insulin release from functioning beta cells in the pancreas; may improve binding between insulin and insulin receptors or increase the number of insulin receptors; more potent in effect than first-generation sulfonylureas.
Indications
-
Adjunct to diet and exercise to lower blood glucose with type 2 diabetes mellitus
Contraindications and Cautions
-
Contraindicated with allergy to sulfonylureas; diabetes mellitus with ketoacidosis, sole therapy of type 1 diabetes mellitus or diabetes mellitus complicated by pregnancy, serious hepatic or renal impairment, uremia; diabetes mellitus complicated by fever, severe infections, severe trauma, major surgery, ketosis, acidosis, coma (insulin is contraindicated).
-
Use cautiously with pregnancy, lactation, thyroid or endocrine impairment, glycosuria, hyperglycemia associated with primary renal disease; labor and delivery (if glyburide is used during pregnancy, discontinue drug at least 1 mo before delivery).
Available Forms
Tablets—1.25, 2.5, 5 mg; micronized tablets—1.5, 3, 4.5, 6 mg
Dosages
Adults
-
Initial therapy: 2.5–5 mg PO with breakfast (DiaBeta); 1.5–3 mg/day PO (Glynase).
-
Maintenance therapy: 1.25–20 mg/day PO given as a single dose or in divided doses. Increase in increments of no more than 2.5 mg (1.5 mg micronized) at weekly intervals based on patient’s blood glucose response (DiaBeta); 0.75–12 mg/day PO (Glynase).
Debilitated or malnourished patients
Start with 1.25 mg daily (nonmicronized) or 0.75 mg daily (micronized).
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
